F-18 16 Alpha-Fluoroestradiol

DRUG9 trials

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Deep Fibromatosis/Desmoid TumorEstrogen Receptor PositiveEstrogen Receptor-Positive Breast CarcinomaEstrogen Receptor-positive Breast CancerFamilial Adenomatous PolyposisHER2/Neu NegativeMale Breast Cancer

Early Phase 1

18F-FES PET/CT in Imaging Patients With Desmoid Tumors

TerminatedNCT02374931

Vanderbilt-Ingram Cancer CenterDeep Fibromatosis/Desmoid Tumor, Familial Adenomatous Polyposis

Start: 2015-04-30End: 2017-12-31Updated: 2019-10-03

Phase 2

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

CompletedNCT00602043

National Cancer Institute (NCI)Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer +2

Start: 2008-09-30End: 2014-09-30Updated: 2020-02-19

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Active, not recruitingNCT02398773

National Cancer Institute (NCI)HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive +1

Start: 2016-05-04End: 2026-03-31Target: 99Updated: 2026-04-03

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

Active, not recruitingNCT04692103

University of WashingtonEstrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7

Start: 2021-07-10End: 2041-04-30Updated: 2026-01-22

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

RecruitingNCT06260033

City of Hope Medical CenterAnatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma

Start: 2024-07-23End: 2026-10-29Target: 18Updated: 2025-10-06

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

RecruitingNCT07112053

University of WashingtonAnatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma

Start: 2025-11-17End: 2028-12-31Target: 40Updated: 2026-03-09

Unknown Phase

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

CompletedNCT01153672

University of WashingtonMale Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer

Start: 2010-11-30End: 2016-08-11Updated: 2019-09-06

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

CompletedNCT01720602

University of WashingtonMale Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer

Start: 2012-11-30End: 2020-01-31Updated: 2020-01-07

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

TerminatedNCT02149173

University of WashingtonEstrogen Receptor Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7

Start: 2010-09-15End: 2021-01-13Updated: 2021-06-30

Related Papers

A phase II clinical trial of HDACi (vorinostat) and AI therapy in breast cancer with molecular imaging correlates.